Literature DB >> 6190593

Recruitment of OKM1 staining lymphocytes with selective binding to K-562 tumour targets by interferon.

R A Salata, B Z Schacter, J J Ellner.   

Abstract

Spontaneous cytotoxicity of human lymphocytes for tumours is increased by interferon (IFN) without change in the overall fraction of cells binding to targets. We developed an indirect immunofluorescent technique to stain lymphocytes conjugated to K-562 tumour cells in agarose with monoclonal antibodies. This allowed assessment of lymphocyte subpopulations binding to tumour cells without disruption of conjugates. Overall binding of non-adherent (NA) lymphocytes to tumour targets following incubation at 37 degrees C for 6 h was 13.3 +/- 0.3% compared to 12.5 +/- 0.7% with inclusion of IFN at 100 u/ml. When NA lymphocytes were incubated with K-562 tumour cells without IFN, OKM1 and OKT3 staining lymphocytes comprised 16.8 +/- 3.5% and 83.0 +/- 1.3% of the total lymphocyte population and 32.5 +/- 1.3% and 70.2 +/- 2.6% of lymphocytes conjugated to tumours. Incubation with IFN significantly increased OKM1 staining cells in the total NA population to 57.2 +/- 5.6% (P less than 0.01) and within tumour conjugates to 59.2 +/- 2.7% (P less than 0.01) while OKT3 staining cells decreased to 58.3 +/- 5.2% (P less than 0.02) and 45.3 +/- 1.2% (P less than 0.01), respectively. IFN increased cytotoxicity of NA cells for 51Cr-labelled K-562 by 66% at an effector to target ratio of 30:1 (P less than 0.001). These results demonstrate that OKM1 staining cells bind more avidly to tumour targets in the absence of IFN. IFN selectively increases the proportion of OKM1 staining lymphocytes with a concomitant increase in their binding to tumour cells. Therefore, enhancement of cytotoxicity by IFN in the NK system may result, in part, from conversion of OKT3 to OKM1 staining cells which are more efficient killers.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6190593      PMCID: PMC1535559     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  24 in total

1.  Human spontaneous killer cells selective for tumour-derived target cells.

Authors:  M Jondal; C Spine; S Targan
Journal:  Nature       Date:  1978-03-02       Impact factor: 49.962

2.  Monoclonal antibodies defining distinctive human T cell surface antigens.

Authors:  P Kung; G Goldstein; E L Reinherz; S F Schlossman
Journal:  Science       Date:  1979-10-19       Impact factor: 47.728

3.  Natural cytotoxic reactivity of human lymphocytes against a myeloid cell line: characterization of effector cells.

Authors:  W H West; G B Cannon; H D Kay; G D Bonnard; R B Herberman
Journal:  J Immunol       Date:  1977-01       Impact factor: 5.422

Review 4.  Natural cell-mediated immunity.

Authors:  R B Herberman; H T Holden
Journal:  Adv Cancer Res       Date:  1978       Impact factor: 6.242

5.  Purification of human T and B lymphocytes.

Authors:  M F Greaves; G Brown
Journal:  J Immunol       Date:  1974-01       Impact factor: 5.422

6.  Enhanced NK cell activity in mice injected with interferon and interferon inducers.

Authors:  M Gidlund; A Orn; H Wigzell; A Senik; I Gresser
Journal:  Nature       Date:  1978-06-29       Impact factor: 49.962

7.  Separation of functional subsets of human T cells by a monoclonal antibody.

Authors:  E L Reinherz; P C Kung; G Goldstein; S F Schlossman
Journal:  Proc Natl Acad Sci U S A       Date:  1979-08       Impact factor: 11.205

8.  Augmentation of mouse natural killer cell activity by interferon and interferon inducers.

Authors:  J Y Djeu; J A Heinbaugh; H T Holden; R B Herberman
Journal:  J Immunol       Date:  1979-01       Impact factor: 5.422

9.  Cell-mediated cytotoxicity against virus-infected target cells in humans. I. Characterization of the effector lymphocyte.

Authors:  D Santoli; G Trinchieri; F S Lief
Journal:  J Immunol       Date:  1978-08       Impact factor: 5.422

10.  Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis.

Authors:  G Trinchieri; D Santoli
Journal:  J Exp Med       Date:  1978-05-01       Impact factor: 14.307

View more
  5 in total

1.  Interferon-alpha induction of lymphocytes containing parallel tubular structures.

Authors:  Y L Hoogeveen; J W Smit; N R Blom; M J van Luyn; R M Halie
Journal:  Blut       Date:  1988-02

2.  Surface markers and cytotoxic activity of blood natural killer cells studied at the single cell level in Hodgkin's disease.

Authors:  E Jezewska; M Björkholm; R Giscombe; G Holm; O Tullgren
Journal:  Clin Exp Immunol       Date:  1985-07       Impact factor: 4.330

3.  Capsaicin Functions as Drosophila Ovipositional Repellent and Causes Intestinal Dysplasia.

Authors:  Yaoxing Li; Peng Bai; Longsheng Wei; Ruxue Kang; Lirong Chen; Mingliang Zhang; Eng King Tan; Wei Liu
Journal:  Sci Rep       Date:  2020-06-19       Impact factor: 4.379

4.  The genome of the stable fly, Stomoxys calcitrans, reveals potential mechanisms underlying reproduction, host interactions, and novel targets for pest control.

Authors:  Pia U Olafson; Serap Aksoy; Geoffrey M Attardo; Greta Buckmeier; Xiaoting Chen; Craig J Coates; Megan Davis; Justin Dykema; Scott J Emrich; Markus Friedrich; Christopher J Holmes; Panagiotis Ioannidis; Evan N Jansen; Emily C Jennings; Daniel Lawson; Ellen O Martinson; Gareth L Maslen; Richard P Meisel; Terence D Murphy; Dana Nayduch; David R Nelson; Kennan J Oyen; Tyler J Raszick; José M C Ribeiro; Hugh M Robertson; Andrew J Rosendale; Timothy B Sackton; Perot Saelao; Sonja L Swiger; Sing-Hoi Sze; Aaron M Tarone; David B Taylor; Wesley C Warren; Robert M Waterhouse; Matthew T Weirauch; John H Werren; Richard K Wilson; Evgeny M Zdobnov; Joshua B Benoit
Journal:  BMC Biol       Date:  2021-03-10       Impact factor: 7.431

Review 5.  Biology of natural killer cells.

Authors:  G Trinchieri
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.